Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.52 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458229 | 0.89 | TNIK (0.61) | TNIKMAPTKCNH2RXFP1 | |
| SCHEMBL5462758 | 0.87 | TNIK (0.54) | TNIKMAPTDUSP3PTPN5PTPN11 | |
| SCHEMBL5452297 | 0.87 | TNIK (0.54) | TNIKMAPTDUSP3PTPN5PTPN11 | |
| SCHEMBL5451267 | 0.86 | TNIK (0.59) | TNIKFLT3MAPTDUSP3PTPN5 | |
| SCHEMBL5448399 | 0.86 | TNIK (0.62) | TNIKMAPTDUSP3PTPN5PTPN11 | |
| SCHEMBL5453345 | 0.86 | TNIK (0.59) | TNIKMAPTDUSP3PTPN5PTPN11 | |
| SCHEMBL5752965 | 0.86 | TNIK (0.74) | TNIKFLT3MAPTDUSP3PTPN5 | |
| SCHEMBL5446149 | 0.86 | TNIK (0.74) | TNIKFLT3MAPTDUSP3PTPN5 | |
| SCHEMBL5459994 | 0.86 | TNIK (0.74) | TNIKFLT3MAPTDUSP3PTPN5 | |
| SCHEMBL5446191 | 0.86 | TNIK (0.59) | TNIKMAPTDUSP3PTPN5PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | TNIK 4134/4885FLT3 3509/4885MAPT 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.